MAPT and Alzheimer disease: Indeed, a radiotracer for α-syn is not yet available as opposed to Alzheimer’s Disease (AD), in which in vivo investigations using radiotracers for beta-amyloid or tau, or CSF determination of biomarker (i.e. phospho-tau, total tau and amyloid β42) levels provides information on the underlying pathology.